# MindRank AI Targets Selective CB1 Receptor Modulation With Novel Heterocyclic Compounds

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/patent-watch-mindrank-ai-targets-selective-cb1-receptor-mo-2026-10-27/
> **Published:** 2026-10-27T11:19:03-04:00 | **Last Modified / Clinically Audited:** 2026-10-27T11:19:03-04:00
> **Clinical Summary:** The patent disclosure describes novel synthetic heterocyclic molecules engineered to selectively regulate cannabinoid CB1 receptor activity. Developed util

---

PATENT WATCH
 19511214
 
 

# MindRank AI Targets Selective CB1 Receptor Modulation With Novel Heterocyclic Compounds

 
 **Assignee:** MINDRANK AI LTD.
 **Inventors:** Long Zhang, Zhangming Niu
 **Published:** 2026-02-13
 
 

 
 Invention Summary & Claims
 

The patent disclosure describes novel synthetic heterocyclic molecules engineered to selectively regulate cannabinoid CB1 receptor activity. Developed utilizing computational drug design, these active pharmaceutical ingredients aim to fine-tune receptor signaling rather than inducing broad, non-selective activation or blockade. This selective approach seeks to isolate therapeutic targets while mitigating the adverse neurobehavioral side effects historically linked to CB1 drugs.

 

 

## Clinical Perspective & Therapeutic Significance

 

Selective modulation of the CB1 receptor holds therapeutic potential for metabolic dysfunction, chronic neuropathic pain, and neuroinflammatory disorders without triggering classic central nervous system liabilities. By isolating specific signaling pathways, these synthetic compounds could offer a wider therapeutic window and superior tolerability compared to standard agonists or antagonists. Rigorous translational studies remain necessary to evaluate human pharmacokinetics, off-target binding, and real-world clinical safety.

 

## Intellectual Property & Market Landscape

 

MindRank AI Ltd. positions itself at the intersection of computational drug discovery and small-molecule development, focusing on proprietary chemical entities rather than botanical extracts. This synthetic approach targets high-value pharmaceutical indications, positioning the intellectual property against conventional biopharmaceutical pipelines rather than commercial dispensary products. If preclinically validated, such targeted molecules could attract strategic licensing partnerships with global pharmaceutical developers seeking refined endocannabinoid assets.

 
 **Official Source Document:** Review the primary patent disclosure and full claims on [Google Patents (19511214)](https://patents.google.com/patent/19511214/en).
 

 
 Editorial Commentary
 

Developing fine-tuned synthetic modulators of the CB1 receptor represents a

 

 

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Cannabis Consultation](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).